Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

by NASDAQ Market News July 29, 2020

NASDAQ Market News
Click here to email author

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

QuestCap Signs Definitive Agreement and Closes Transaction to Acquire 28% Interest in Colombian Full-Service Medical Clinic

Ads